Genetic and Environmental Factors Associated with Cannabis Involvement

Current Addiction Reports

Volumn 3, Issue 2, 2016, Pages 199-213

  Bogdan, Ryan ^a   Winstone, Jonathan M A ^a   Agrawal, Arpana ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adversity; Cannabis; Endocannabinoid; Gene; Imaging genetics; Neurogenetics

Indexed keywords

EID: 85013165711     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-016-0103-1     Document Type: Review

References (106)

1. Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use: 1975–2014: overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan; 2015. This recent report characterizes drug use patterns in the United States among adolescents, college students, and adult high school graduates.
2. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;21:1–9. Recent report from the National Epidemiologic Survey of Alcohol and Related Conditions (n = 36,309) indicating that the past-year prevalence of cannabis use has increased from 4.1 % in 2001–2002 to 9.5 % in 2012–2013. Rates of past year cannabis use disorders have more nearly doubled; however, the conditional prevalence (cannabis use disorder among users) has decreased.
3. Drug Abuse Warning Network. In: Administration SAaMHS, editor. 2011: national estimates of drug-related emergency department visits. Rockville: Substance Abuse and Mental Health Services Administration; 2013.
4. Verweij KJ, Zietsch BP, Lynskey MT, Medland SE, Neale MC, Martin NG, et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction. 2010;105(3):417–30. Meta-analysis of twin studies of cannabis use and problem use indicating that heritable variation is responsible for a substantial proportion of the variance in these behaviors.
5. Kendler KS, Schmitt E, Aggen SH, Prescott CA. Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch Gen Psychiatry. 2008;65(6):674–82. Twins recalled how often they had used cannabis between the ages of 14 to 41 years. The identical and fraternal twin correlations were approximately equal at earlier ages, diverging at age 22 and again in the late 20s. These differences in the identical and fraternal twin pair correlations in the 20s reflect emergence of genetic influences on cannabis consumption.
6. Hines LA, Morley KI, Strang J, Agrawal A, Nelson EC, Statham D, et al. The association between speed of transition from initiation to subsequent use of cannabis and later problematic cannabis use, abuse and dependence. Addiction. 2015;110(8):1311–20.
7. Gillespie NA, Neale MC, Kendler KS. Pathways to cannabis abuse: a multi-stage model from cannabis availability, cannabis initiation and progression to abuse. Addiction. 2009;104(3):430–8. A twin study of males twins showing that most of the familial environmental, but not genetic or person-specific environmental, variation in cannabis initiation and problems overlaps with availability. Genetic (62 %) and person-specific environmental (82 %) influences on cannabis problems also overlap with those on initiation.
8. Bierut LJ, Dinwiddie SH, Begleiter H, Crowe RR, Hesselbrock V, Nurnberger Jr JI, et al. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the collaborative study on the genetics of alcoholism. Arch Gen Psychiatry. 1998;55(11):982–8.
9. Merikangas KR, Li JJ, Stipelman B, Yu K, Fucito L, Swendsen J, et al. The familial aggregation of cannabis use disorders. Addiction. 2009;104(4):622–9.
10. Kendler KS, Myers J, Prescott CA. Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry. 2007;64(11):1313–20.
11. Tsuang MT, Bar JL, Harley RM, Lyons MJ. The Harvard twin study of substance abuse: what we have learned. Harv Rev Psychiatry. 2001;9(6):267–79.
12. Palmer RH, Young SE, Corley RP, Hopfer CJ, Stallings MC, Hewitt JK. Stability and change of genetic and environmental effects on the common liability to alcohol, tobacco, and cannabis DSM-IV dependence symptoms. Behav Genet. 2013;43(5):374–85.
13. Vrieze SI, Hicks BM, Iacono WG, McGue M. Decline in genetic influence on the co-occurrence of alcohol, marijuana, and nicotine dependence symptoms from age 14 to 29. Am J Psychiatry. 2012;169(10):1073–81.
14. Grant JD, Lynskey MT, Madden PA, Nelson EC, Few LR, Bucholz KK, et al. The role of conduct disorder in the relationship between alcohol, nicotine and cannabis use disorders. Psychol Med. 2015;45(16):3505–15.
15. Devane WA, Dysarz 3rd FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605–13.
16. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–4.
17. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5.
18. De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab. 2009;23(1):1–15.
19. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001;58(4):322–8.
20. Lichtman AH, Martin BR. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav. 1997;57(1–2):7–12.
21. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17(6):642–9.
22. Agrawal A, Pergadia ML, Saccone SF, Lynskey MT, Wang JC, Martin NG, et al. An autosomal linkage scan for cannabis use disorders in the nicotine addiction genetics project. Arch Gen Psychiatry. 2008;65(6):713–21.
23. Agrawal A, Wetherill L, Dick DM, Xuei X, Hinrichs A, Hesselbrock V, et al. Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(5):736–40.
24. Bidwell LC, Metrik J, McGeary J, Palmer RH, Francazio S, Knopik VS. Impulsivity, variation in the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes, and marijuana-related problems. J Stud Alcohol Drugs. 2013;74(6):867–78.
25. Carey CE, Agrawal A, Zhang B, Conley ED, Degenhardt L, Heath AC, et al. Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala reactivity: evidence from an endocannabinoid system-level analysis. J Abnorm Psychol. 2015;124(4). In a discovery and replication sample, this study showed that a polymorphism within MGLL interacts with childhood adversity to predict symptoms of cannabis dependence. Specifically, A allele carriers at rs604300 were protected from elevations in cannabis dependence symptoms related to childhood adversity. In a third sample, A carriers further showed enhanced amygdala habituation in the context of childhood adversity which may potentially contribute to reduced urges to use marijuana to control one’s mood.
26. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G, et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry. 1997;2(2):161–8.
27. Hartman CA, Hopfer CJ, Haberstick B, Rhee SH, Crowley TJ, Corley RP, et al. The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. Drug Alcohol Depend. 2009;104(1–2):11–6.
28. Haughey HM, Marshall E, Schacht JP, Louis A, Hutchison KE. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction. 2008;103(10):1678–86.
29. Herman AI, Kranzler HR, Cubells JF, Gelernter J, Covault J. Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(5):499–503.
30. Hopfer CJ, Young SE, Purcell S, Crowley TJ, Stallings MC, Corley RP, et al. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(8):895–901.
31. Krebs MO, Morvan Y, Jay T, Gaillard R, Kebir O. Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students. Mol Psychiatry. 2014;19(4):402–3.
32. Schacht JP, Selling RE, Hutchison KE. Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis. Psychopharmacology (Berlin). 2009;203(3):511–7.
33. Tyndale RF, Payne JI, Gerber AL, Sipe JC. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(5):660–6.
34. Benyamina A, Kebir O, Blecha L, Reynaud M, Krebs MO. CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addict Biol. 2011;16(1):1–6.
35. Chiang K. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet. 2004;13(18):2113–9.
36. Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, Le Foll B, et al. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB. J Cereb Blood Flow Metab. 2015;35(8):1237–40.
37. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology. 2010;35(4):967–75. This imaging genetics study links variation in CNR1 and FAAH to neural responses to marijuana cues among abstaining users. Specifically, genotypes previously linked to cannabis use disorders and related phenotypes were associated with potentiated reactivity in reward-related brain regions when exposed to cannabis cues. This research identified a promising neural mechanism that may potentiate risk for cannabis use disorder.
38. Buhler KM, Gine E, Echeverry-Alzate V, Calleja-Conde J, de Fonseca FR, Lopez-Moreno JA. Common single nucleotide variants underlying drug addiction: more than a decade of research. Addict Biol. 2015;20(5):845–71.
39. Creemers HE, Harakeh Z, Dick DM, Meyers J, Vollebergh WA, Ormel J, et al. DRD2 and DRD4 in relation to regular alcohol and cannabis use among adolescents: does parenting modify the impact of genetic vulnerability? The TRAILS study. Drug Alcohol Depend. 2011;115(1–2):35–42.
40. Jutras-Aswad D, Jacobs MM, Yiannoulos G, Roussos P, Bitsios P, Nomura Y, et al. Cannabis-dependence risk relates to synergism between neuroticism and proenkephalin SNPs associated with amygdala gene expression: case–control study. PLoS One. 2012;7(6), e39243.
41. Duncan LE, Keller MC. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am J Psychiatry. 2011;168(10):1041–9.
42. Tobacco GC. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42(5):441–7.
43. Vink JM, Hottenga JJ, de Geus EJ, Willemsen G, Neale MC, Furberg H, et al. Polygenic risk scores for smoking: predictors for alcohol and cannabis use? Addiction. 2014;109(7):1141–51.
44. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5):448–53.
45. Agrawal A, Lynskey MT, Kapoor M, Bucholz KK, Edenberg HJ, Schuckit M, et al. Are genetic variants for tobacco smoking associated with cannabis involvement? Drug Alcohol Depend. 2015;150:183–7.
46. Agrawal A, Lynskey MT, Hinrichs A, Grucza R, Saccone SF, Krueger R, et al. A genome-wide association study of DSM-IV cannabis dependence. Addict Biol. 2011;16(3):514–8.
47. Agrawal A, Lynskey MT, Bucholz KK, Kapoor M, Almasy L, Dick DM, et al. DSM-5 cannabis use disorder: a phenotypic and genomic perspective. Drug Alcohol Depend. 2014;134:362–9.
48. Verweij KJ, Vinkhuyzen AA, Benyamin B, Lynskey MT, Quaye L, Agrawal A, et al. The genetic aetiology of cannabis use initiation: a meta-analysis of genome-wide association studies and a SNP-based heritability estimation. Addict Biol. 2013;18(5):846–50. A large genomewide association study of cannabis initiation and age at onset using data on common and rare variants. SNPs explained 25 % of the variance in initiation with chromosomes 4 and 18 providing major proportions of this variation. No single variant was significant at a genome-wide significant level. SNPs of causal effect may be in related regions on these chromosomes but not typed on common platforms.
49. Minica CC, Dolan CV, Hottenga JJ, Pool R, Genome of the Netherlands C, Fedko IO, et al. Heritability, SNP- and gene-based analyses of cannabis use initiation and age at onset. Behav Genet. 2015;45(5):503–13.
50. Palmer RH, Brick L, Nugent NR, Bidwell LC, McGeary JE, Knopik VS, et al. Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. Addiction. 2015;110(3):530–7.
51. Power RA, Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014;19(11):1201–4. Cannabis use has been implicated in the etiology of schizophrenia. This recent study suggests that polygenic risk for schizophrenia may be associated with liability to use cannabis, providing evidence for shared genetic etiologies.
52. Bogdan R, Hyde LW, Hariri AR. A neurogenetics approach to understanding individual differences in brain, behavior, and risk for psychopathology. Mol Psychiatry. 2013;18(3):288–99.
53. Bogdan R, Pagliaccio D, Baranger DA, Hariri AR. Genetic moderation of stress effects on corticolimbic circuitry. Neuropsychopharmacology. 2015.
54. Conzelmann A, Reif A, Jacob C, Weyers P, Lesch KP, Lutz B, et al. A polymorphism in the gene of the endocannabinoid-degrading enzyme FAAH (FAAH C385A) is associated with emotional-motivational reactivity. Psychopharmacology (Berlin). 2012;224(4):573–9.
55. Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur J Neurosci. 2006;23(7):1944–8.
56. Colizzi M, Fazio L, Ferranti L, Porcelli A, Masellis R, Marvulli D, et al. Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior. Neuropsychopharmacology. 2015;40(3):640–9.
57. Demers CH, Conley ED, Bogdan R, Hariri AR. Interactions between anandamide & corticotropin-releasing hormone signaling modulate human amygdala function & risk for anxiety disorders: an imaging genetics strategy for modeling molecular interactions. Biol Psychiatry. 2016.
58. Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC, et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. 2015;6:6395.
59. Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B, et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry. 2013;18(7):813–23. This cross-species study provides evidence that anandamide signaling facilitates fear extinction to reduce fear and promote stress-related coping. In rodents, FAAH inhibition before extinction reduces fear during a retrieval test. Further it showed that among rodents, extinction increased anandamide levels in the basolateral amygdala, which was augmented by FAAH inhibition. FAAH inhibition promoted long-term depression of inhibitory neurotransmission in the amygdala provided a putative mechanism through which endocannabinoid signaling may facilitate extinction. Further, among humans, the A allele at rs324420, which is associated with reduced FAAH expression, exhibited quicker habituation of the amygdala to threat-related stimuli and less self-reported stress reactivity.
60. Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F, et al. Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol Psychiatry. 2009;66(1):9–16.
61. Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res. 2011;128(1–3):66–75.
62. Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S, Andreasen NC, et al. MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med. 2013;43(3):619–31.
63. Schacht JP, Hutchison KE, Filbey FM. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology. 2012;37(11):2368–76.
64. Shollenbarger SG, Price J, Wieser J, Lisdahl K. Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults. Neuroimage Clin. 2015;8:117–25.
65. Stadelmann AM, Juckel G, Arning L, Gallinat J, Epplen JT, Roser P. Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neurosci Lett. 2011;496(1):60–4.
66. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci. 2013;34(11):637–44.
67. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–38.
68. Gillespie NA, Lubke GH, Gardner CO, Neale MC, Kendler KS. Two-part random effects growth modeling to identify risks associated with alcohol and cannabis initiation, initial average use and changes in drug consumption in a sample of adult, male twins. Drug Alcohol Depend. 2012;123(1–3):220–8. A twin study that found that the cannabis use leads to affiliation with deviant peers and that a significant proportion of the genetic and environmental influences in peer group deviance are shared with similar influences on cannabis use.
69. Tarter RE, Fishbein D, Kirisci L, Mezzich A, Ridenour T, Vanyukov M. Deviant socialization mediates transmissible and contextual risk on cannabis use disorder development: a prospective study. Addiction. 2011;106(7):1301–8.
70. Sartor CE, Agrawal A, Grant JD, Duncan AE, Madden PA, Lynskey MT, et al. Differences between African-American and European-American women in the association of childhood sexual abuse with initiation of marijuana use and progression to problem use. J Stud Alcohol Drugs. 2015;76(4):569–77.
71. Gillespie NA, Neale MC, Jacobson K, Kendler KS. Modeling the genetic and environmental association between peer group deviance and cannabis use in male twins. Addiction. 2009;104(3):420–9.
72. Kendler KS, Jacobson KC, Gardner CO, Gillespie N, Aggen SA, Prescott CA. Creating a social world: a developmental twin study of peer-group deviance. Arch Gen Psychiatry. 2007;64(8):958–65.
73. Bohnert KM, Anthony JC, Breslau N. Parental monitoring at age 11 and subsequent onset of cannabis use up to age 17: results from a prospective study. J Stud Alcohol Drugs. 2012;73(2):173–7.
74. Dick DM, Viken R, Purcell S, Kaprio J, Pulkkinen L, Rose RJ. Parental monitoring moderates the importance of genetic and environmental influences on adolescent smoking. J Abnorm Psychol. 2007;116(1):213–8.
75. Rose RJ, Dick DM, Commentary on Agrawal, et al. Social environments modulate alcohol use. Addiction. 2010;105(10):1854–5.
76. Distel MA, Vink JM, Bartels M, van Beijsterveldt CE, Neale MC, Boomsma DI. Age moderates non-genetic influences on the initiation of cannabis use: a twin-sibling study in Dutch adolescents and young adults. Addiction. 2011;106(9):1658–66.
77. Vink JM, Wolters LM, Neale MC, Boomsma DI. Heritability of cannabis initiation in Dutch adult twins. Addict Behav. 2010;35(2):172–4. This study utilized effect sizes from one of the largest meta-analyses of genome-wide association study data for cigarette smoking to generate polygenic risk scores in an independent sample of Dutch twins. Polygenic risk scores for cigarettes smoked per day were associated with cannabis initiation in this independent sample, suggesting that the cumulative and additive effects of variants associated with tobacco smoking also influence liability to cannabis use.
78. Waldron M, Heath AC, Turkheimer EN, Emery RE, Nelson E, Bucholz KK, et al. Childhood sexual abuse moderates genetic influences on age at first consensual sexual intercourse in women. Behav Genet. 2008;38(1):1–10.
79. Nelson EC, Agrawal A, Pergadia ML, Wang JC, Whitfield JB, Saccone FS, et al. H2 haplotype at chromosome 17q21.31 protects against childhood sexual abuse-associated risk for alcohol consumption and dependence. Addict Biol. 2010;15(1):1–11.
80. Gray JM, Vecchiarelli HA, Morena M, Lee TT, Hermanson DJ, Kim AB, et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci. 2015;35(9):3879–92. This study characterized FAAH × CRHR1 interactions that contribute to amygdala function and anxiety using a rodent model.
81. Buwembo A, Long H, Walker CD. Participation of endocannabinoids in rapid suppression of stress responses by glucocorticoids in neonates. Neuroscience. 2013;249:154–61.
82. El Rawas R, Thiriet N, Nader J, Lardeux V, Jaber M, Solinas M. Early exposure to environmental enrichment alters the expression of genes of the endocannabinoid system. Brain Res. 2011;1390:80–9.
83. Lee TT, Hill MN. Age of stress exposure modulates the immediate and sustained effects of repeated stress on corticolimbic cannabinoid CB(1) receptor binding in male rats. Neuroscience. 2013;249:106–14.
84. Lisdahl KM, Wright NE, Kirchner-Medina C, Maple KE, Shollenbarger S. The effects of regular cannabis use on neurocognition in adolescents and young adults. Current addiction reports. 2014;1(2):144–56.
85. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13):2186–93.
86. Lorenzetti V, Solowij N, Fornito A, Lubman DI, Yucel M. The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature. Curr Pharm Des. 2014;20(13):2138–67.
87. Agrawal A, Lynskey MT. Have the genetics of cannabis involvement gone to pot? Neb Symp Motiv. 2014;61:71–108.
88. Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2015.
89. Hickman M, Vickerman P, Macleod J, Lewis G, Zammit S, Kirkbride J, et al. If cannabis caused schizophrenia—how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction. 2009;104(11):1856–61.
90. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol Psychiatry. 2005;57(10):1117–27.
91. French L, Gray C, Leonard G, Perron M, Pike GB, Richer L, et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry. 2015;72(10):1002–11.
92. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.
93. Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Psychol Med. 2015;45(2):407–14.
94. Consortium C. Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature. 2015;523(7562):588–91.
95. Major Depressive Disorder Working Group of the Psychiatric GC, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2013;18(4):497–511.
96. Boardman JD, Blalock CL, Pampel FC, Hatemi PK, Heath AC, Eaves LJ. Population composition, public policy, and the genetics of smoking. Demography. 2011;48(4):1517–33.
97. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics C, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291–5.
98. Hibar DP, Stein JL, Renteria ME, Arias-Vasquez A, Desrivieres S, Jahanshad N, et al. Common genetic variants influence human subcortical brain structures. Nature. 2015;520(7546):224–9.
99. Musliner KL, Seifuddin F, Judy JA, Pirooznia M, Goes FS, Zandi PP. Polygenic risk, stressful life events and depressive symptoms in older adults: a polygenic score analysis. Psychol Med. 2015;45(8):1709–20.
100. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636–45.
101. Rose EJ, Donohoe G. Brain vs behavior: an effect size comparison of neuroimaging and cognitive studies of genetic risk for schizophrenia. Schizophr Bull. 2013;39(3):518–26.
102. Munafo MR, Flint J. The genetic architecture of psychophysiological phenotypes. Psychophysiology. 2014;51(12):1331–2.
103. Gorka SM, Fitzgerald DA, de Wit H, Phan KL. Cannabinoid modulation of amygdala subregion functional connectivity to social signals of threat. Int J Neuropsychopharmacol. 2015;18(3).
104. Duncan AE, Sartor CE, Scherrer JF, Grant JD, Heath AC, Nelson EC, et al. The association between cannabis abuse and dependence and childhood physical and sexual abuse: evidence from an offspring of twins design. Addiction. 2008;103(6):990–7.
105. Szutorisz H, Hurd YL. Epigenetic effects of cannabis exposure. Biol Psychiatry. 2015.
106. Arloth J, Bogdan R, Weber P, Frishman G, Menke A, Wagner KV, et al. Genetic differences in the immediate transcriptome response to stress predict risk-related brain function and psychiatric disorders. Neuron. 2015;86(5):1189–202.